Boehringer Ingelheim and Biolipox Sign Agreement on a New Class of Drugs to Treat Pain and Inflammation STOCKHOLM, Sweden, Nov. 14, 2005 (PRIMEZONE) -- Boehringer Ingelheim GmbH and Biolipox announced today that they agreed to a worldwide exclusive research and license collaboration. The aim of the...

Biolipox Reports Rapid Relief with NLA Nasal Spray in New Clinical Trial STOCKHOLM, Sweden, Feb. 22, 2005 (PRIMEZONE) -- Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases, announced today that it has successfully...

Biolipox -- Year-end Report 2004 STOCKHOLM, Sweden, Feb. 21, 2005 (PRIMEZONE) -- Biolipox: Full-year 2004 -- Biolipox secure additional funding -- international venture capital firms invest EUR 30 million -- NLA Nasal...

Biolipox Joins Top-Ranked EU Project STOCKHOLM, Sweden, Feb. 17, 2005 (PRIMEZONE) -- Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases, today announces that it has been selected to...

Biolipox Announces Positive Results from Clinical Phase II Trial in Rhinitis STOCKHOLM, Sweden, June 1, 2004 (PRIMEZONE) -- Biolipox, a research intensive pharmaceutical company targeting inflammation and respiratory diseases, today announced positive preliminary results from...